Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)

Blood (2016) 128 (22): 464.

https://doi.org/10.1182/blood.V128.22.464.464

Published: 2016

Journal Articles

Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models

Blood (2016) 128 (22): 4465.

https://doi.org/10.1182/blood.V128.22.4465.4465

Published: 2016

Journal Articles

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

Auayporn Nademanee, MD, Andrew Raubitschek, MD, Arturo Molina, MD, Joycelynne Palmer, Ph.D, Ni-Chun Tsai, MS, Amrita Krishnan, MD, Neil Kogut, MD, Stephen Forman, MD

Blood (2007) 110 (11): 1891.

https://doi.org/10.1182/blood.V110.11.1891.1891

Published: 2007

Journal Articles

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Andrew Raubitschek, MD, Henry C. Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter M. Falk, MD, Ricardo Spielberger, MD, Joycelynne Palmer, PhD, Ni Chun Tsai, MS, MPH, Jeffrey Schriber, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3043.

https://doi.org/10.1182/blood.V108.11.3043.3043

Published: 2006

Journal Articles

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

John C. Byrd, MD, Januario Castro, MD, Susan O’Brien, MD, Ian W. Flinn, MD, Andres Forero-Torres, MD, Thomas J. Kipps, MD, PhD, Nyla A. Heerema, PhD, Thomas Lin, MD, Thian Kheoh, PhD, Dee Wynnem, RN, Arturo Molina, MD, MS

Blood (2006) 108 (11): 32.

https://doi.org/10.1182/blood.V108.11.32.32

Published: 2006

Journal Articles

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Edward Agura, MD, R. Brian Berryman, MD, Laura Brougher, RN, Barry Cooper, MD, Andrew De Leon, RPh, Joseph Fay, MD, Houston Holmes, MD, Christopher Maisel, MD, Arturo Molina, MD, Luis Pineiro, MD, Giovanna Saracino, MD, Mirjana Tadic-Ovcina, MD, Estil Vance, MD

Blood (2006) 108 (11): 1951.

https://doi.org/10.1182/blood.V108.11.1951.1951

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation (ASCT) for AIDS-Related Lymphomas (ARL) and the Potential Role of HIV-Resistant Stem Cells.

Amrita Y. Krishnan, MD, John A. Zaia, MD, John J. Rossi, PhD, Arturo Molina, MD, Mingjie Li, PhD, Wendy Lee, Ramesh Akkina, DVM, Nicole Tsai, MS, Shirley Li, MD, Priscilla Yam, FIBMS, Haitang Li, Jiing-Kuan Yee, PhD, David Hsu, PhD, Larry Couture, PhD, David DiGiusto, PhD, Stephen J. Forman, MD

Blood (2006) 108 (11): 491.

https://doi.org/10.1182/blood.V108.11.491.491

Published: 2006

Journal Articles

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

Amrita Krishnan, MD, Andrew Raubitschek, MD, Stephen J. Forman, MD, Henry Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter Falk, MD, Ricardo Spielberger, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Pablo Parker, MD, Warren Chow, MD, Ryoto Nakamura, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 681.

https://doi.org/10.1182/blood.V106.11.681.681

Published: 2005

Journal Articles

Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

Jonathan W. Friedberg, MD, John P. Leonard, MD, Anas Younes, MD, David C. Fisher, MD, Leo I. Gordon, MD, Joseph O. Moore, MD, Myron S. Czuczman, MD, Thomas P. Miller, MD, Patrick J. Stiff, MD, Bruce D. Cheson, MD, Andres Forero-Torres, MD, Deborah M. Finucane, PhD, Bryan R. Leigh, MD, Arturo Molina, MD

Blood (2005) 106 (11): 2435.

https://doi.org/10.1182/blood.V106.11.2435.2435

Published: 2005

Journal Articles

Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.

Leslie L. Popplewell, MD, A. Nademanee, MD, Nora Carter, Jasmine Zain, MD, Amrita Krishnan, MD, Roberto Rodriguez, MD, Neil M. Kogut, MD, Nayana Vora, MD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 894.

https://doi.org/10.1182/blood.V104.11.894.894

Published: 2004

Journal Articles

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Russell J. Schilder, MD, Thomas E. Witzig, MD, Ian Flinn, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Hua Wang, MS, Katie Vo, Arturo Molina, MD.

Blood (2004) 104 (11): 2629.

https://doi.org/10.1182/blood.V104.11.2629.2629

Published: 2004

Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD

Blood (2004) 104 (11): 2634.

https://doi.org/10.1182/blood.V104.11.2634.2634

Published: 2004

Journal Articles

Evaluation of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Non-Hodgkin’s Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT).

Samuel A. Jacobs, MD, Barry McCook, MD, Frank Torok, MD, Norbert Avril, MD, Nick Vidnovic, Judy Joyce, MD, Arturo Molina, MD

Blood (2004) 104 (11): 5238.

https://doi.org/10.1182/blood.V104.11.5238.5238

Published: 2004

Journal Articles

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Henry C. Fung, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Zaid Al Kadhimi, MD, Mark Kirschbaum, MD, Neil Kogut, MD, Andrew Raubitschek, MD, Jeffrey Schriber, MD, Jasmine Zain, MD, Eileen Smith, MD, Nigel Cheng, Dajun Qian, PhD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 5115.

https://doi.org/10.1182/blood.V104.11.5115.5115

Published: 2004

NARROW

Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)

Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Autologous Stem Cell Transplantation (ASCT) for AIDS-Related Lymphomas (ARL) and the Potential Role of HIV-Resistant Stem Cells.

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Evaluation of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Non-Hodgkin’s Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT).

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only